

Pharmaceutical Management Agency

Section H Update for Hospital Pharmaceuticals

Effective 1 August 2019



Contents

Summary of decisions effective 1 August 2019.....	3
Section H changes to Part II	7
Index.....	16

Summary of decisions

EFFECTIVE 1 AUGUST 2019

- Adalimumab inj 20 mg per 0.4 ml syringe and 40 mg per 0.8 ml syringe (Humira) and inj 40 mg per 0.8 ml pen (HumiraPen) – amended restriction criteria
- Amisulpride (Sulprix) tab 100 mg and 200 mg – price increase and addition of HSS
- Aspirin (Ethics Aspirin EC) tab 100 mg – price decrease and addition of HSS
- Azathioprine (Azamun) tab 25 mg and 50 mg – new listing
- Azathioprine (Imuran) tab 25 mg and 50 mg – to be delisted 1 January 2020
- Azathioprine (Imuran) inj 50 mg vial – price increase and addition of HSS
- Bevacizumab inj 25 mg per ml, 4 ml and 16 ml vial – amended restriction criteria
- Bupivacaine hydrochloride with fentanyl (Bupafen) inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml and 200 ml bag – price increase and addition of HSS
- Caffeine citrate (Biomed) oral liq 20 mg per ml (caffeine 10 mg per ml) and inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – price increase and addition of HSS
- Calcium folinate (Calcium Folate Sandoz) inj 10 mg per ml, 10 ml and 35 ml vial – price increase and addition of HSS
- Calcium folinate (Calcium Folate Ebewe) inj 10 mg per ml, 10 ml vial – to be delisted 1 January 2020
- Cefalexin (Cephalexin ABM) cap 250 mg – price decrease and addition of HSS
- Ceftriaxone (Ceftriaxone-AFT) inj 500 mg and 1 g vial – new listing
- Ceftriaxone (DEVA) inj 500 mg and 1 g vial – to be delisted 1 January 2020
- Ceftriaxone (Ceftriaxone-AFT) inj 2 g vial – price decrease and addition of HSS
- Cefuroxime (Zinnat) tab 250 mg – price increase and addition of HSS
- Cetirizine hydrochloride (Zista) tab 10 mg – price increase and addition of HSS
- Chloramphenicol (Chlorafast) eye drops 0.5% – addition of HSS
- Chlorpromazine hydrochloride (Largactil) tab 10 mg, 25 mg and 100 mg and inj 25 mg per ml, 2 ml ampoule – new listing
- Clobetasol propionate (Dermol) crm 0.05%, oint 0.05% and scalp app 0.05% – price decrease and addition of HSS
- Coal tar (Midwest) soln, BP, 200 ml – price increase and addition of HSS
- Dalteparin (Fragmin) inj 2,500 iu in 0.2 ml syringe, 5,000 iu in 0.2 ml syringe, 7,500 iu in 0.75 ml syringe and 10,000 iu in 1 ml syringe – to be delisted 1 April 2020

Summary of decisions – effective 1 August 2019 (continued)

- Dalteparin (Fragmin) inj 12,500 iu in 0.5 ml syringe, 15,000 iu in 0.6 ml syringe and 18,000 iu in 0.72 ml syringe – to be delisted 1 January 2020
 - Digoxin tab 62.5 mcg (Lanoxin PG) and tab 250 mcg (Lanoxin) – price increase and addition of HSS
 - Ethosuximide (Zarontin) cap 250 mg, 100 cap – new listing
 - Ethosuximide (Zarontin) cap 250 mg, 200 cap – to be delisted 1 November 2019
 - Fentanyl (Biomed) inj 10 mcg per ml, 100 ml bag – price increase and addition of HSS
 - Ferrous sulfate (Ferodan) oral liq 30 mg (6 mg elemental) per ml – amended chemical name, price increase and addition of HSS
 - Fludarabine phosphate (Fludarabine Ebewe) inj 50 mg vial – price increase and addition of HSS
 - Furosemide [frusemide] (Apo-Furosemide) tab 40 mg – new listing
 - Furosemide [frusemide] (Diurin 40) tab 40 mg – to be delisted 1 December 2019
 - Furosemide [frusemide] (Lasix) oral liq 10 mg per ml and inj 10 mg per ml, 25 ml ampoule – new listing
 - Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 AND 58) vaccine [HPV] (Gardasil 9) inj 270 mcg in 0.5 ml syringe – amended restriction criteria
 - Hyaluronic acid with lidocaine [lignocaine] inj 20 mg per ml – new listing
 - Hydrocortisone acetate with pramoxine hydrochloride topical aerosol foam, 1% with pramoxine hydrochloride 1% – new listing
 - Iloprost (Clinect) inj 50 mcg in 0.5 ml ampoule – new listing
 - Iloprost (Ilomedin) inj 50 mcg in 0.5 ml ampoule – to be delisted 1 January 2020
 - Intra-uterine device IUD 29.1 mm length x 23.2 mm width (Choice TT380 Short), IUD 33.6 mm length x 29.9 mm width (Choice TT380 Standard) and IUD 35.5 mm length x 19.6 mm width (Choice Load 375) – price decrease and addition of HSS
 - Ipratropium bromide (Univent) nebuliser soln 250 mcg per ml, 2 ml ampoule – price increase and addition of HSS
 - Iron polymaltose (Ferrum H) inj 50 mg per ml, 2 ml ampoule – new listing
 - Itraconazole (Itrazole) cap 100 mg – price increase and addition of HSS
 - Ketamine (Ketamine-Clarix) inj 100 mg per ml, 2 ml vial – new listing
 - Labetalol tab 400 mg – delisted 1 August 2019
-

Summary of decisions – effective 1 August 2019 (continued)

- Lactulose (Laevolac) oral liq 10 g per 15 ml – price increase and addition of HSS
- Lidocaine [lignocaine] hydrochloride (Lidocaine-Clarix) inj 2%, 5 ml ampoule – price increase and addition of HSS
- Lidocaine [lignocaine] hydrochloride with adrenaline (Xylocaine) inj 1% with adrenaline 1:100,000, 5 ml ampoule – price increase and addition of HSS
- Lysine acetylsalicylate (e.g. Aspegic) inj 500 mg – new listing
- Magnesium hydroxide suspension – new listing
- Mesna (Uromitexan) tab 400 mg and 600 mg and inj 100 mg per ml, 4 ml and 10 ml ampoule – price increase and addition of HSS
- Montelukast (Montelukast Mylan) tab 4 mg and 10 mg – new listing
- Montelukast (Apo-Montelukast) tab 4 mg and 10 mg – to be delisted 1 January 2020
- Paracetamol (Biomed) suppos 25 mg and 50 mg – price increase and addition of HSS
- Pentamidine isethionate (Pentacarinat) inj 300 mg vial – price increase and addition of HSS
- Phenoxybenzamine hydrochloride inj 50 mg per ml, 1 ml ampoule – new listing
- Pyridostigmine bromide (Mestinon) tab 60 mg – price increase and addition of HSS
- Pyridoxine hydrochloride inj 100 mg per ml, 2 ml vial – new listing
- Ranitidine (Zantac) inj 25 mg per ml, 2 ml ampoule – price increase
- Rituximab (Mabthera) inj 10 mg per ml, 10 ml and 50 ml vial – amended restriction criteria
- Roxithromycin (Rulide D) tab dispersible 50 mg – price increase
- Spironolactone (Biomed) oral liq 5 mg per ml – price increase and addition of HSS
- Sodium bicarbonate (Midwest) powder BP, 500 g – new listing
- Sodium chloride (Biomed) nebuliser soln 7%, 90 ml bottle – price increase and addition of HSS
- Sodium citrate with sodium lauryl sulfoacetate (Micolette) enema 90 mg with sodium lauryl sulfoacetate 9 mg per ml, 5 ml – price increase and addition of HSS
- Sodium cromoglicate (Rexacrom) eye drops 2% – new listing
- Syrup (Midwest) liq (pharmaceutical grade), 500 ml – new listing

Summary of decisions – effective 1 August 2019 (continued)

- Syrup (Midwest) liq (pharmaceutical grade), 2,000 ml – to be delisted
1 January 2020
- Theophylline tab long-acting 250 mg (Nuelin-SR) and oral liq 80 mg per 15 ml
(Nuelin) – new listing
- Timolol (Timoptol XE) eye drops 0.25%, gel forming, 2.5 ml – to be delisted
1 January 2020
- Warfarin sodium (Marevan) tab 1 mg, 3 mg and 5 mg – price increase

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 August 2019

ALIMENTARY TRACT AND METABOLISM

6	HYDROCORTISONE ACETATE WITH PRAMOXINE HYDROCHLORIDE (new listing) Topical aerosol foam, 1% with pramoxine hydrochloride 1%			
7	RANITIDINE († price) Inj 25 mg per ml, 2 ml ampoule	13.40	5	Zantac
12	LACTULOSE († price and addition of HSS) Oral liq 10 g per 15 ml – 1% DV Nov-19 to 2022	3.33	500 ml	Laevolac
12	SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE († price and addition of HSS) Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Nov-19 to 2022	29.98	50	Micolette
18	FERROUS SULPHATE SULFATE (amended chemical name, † price and addition of HSS) Oral liq 30 mg (6 mg elemental) per ml – 1% DV Nov-19 to 2022	12.08	500 ml	Ferodan
18	IRON POLYMALTOSE (new listing) Inj 50 mg per ml, 2 ml ampoule	15.22	5	Ferrum H
19	HYALURONIC ACID WITH LIDOCAINE [LIGNOCAINE] (new listing) Inj 20 mg per ml			
21	PYRIDOXINE HYDROCHLORIDE (new listing) Inj 100 mg per ml, 2 ml vial			
31	LYSINE ACETYLSALICYLATE (new listing) → Inj 500 mg Restricted Initiation Both: 1 For use when an immediate antiplatelet effect is required prior to an urgent interventional neuro-radiology or interventional cardiology procedure; and 2 Administration of oral aspirin would delay the procedure.			<i>e.g. Aspegic</i>

BLOOD AND BLOOD FORMING ORGANS

29	DALTEPARIN (delisting) Inj 2,500 iu in 0.2 ml syringe	19.97	10	Fragmin
	Inj 5,000 iu in 0.2 ml syringe	39.94	10	Fragmin
	Inj 7,500 iu in 0.75 ml syringe	60.03	10	Fragmin
	Inj 10,000 iu in 1 ml syringe	77.55	10	Fragmin
Note – Fragmin inj 2,500 iu in 0.2 ml syringe, 5,000 iu in 0.2 ml syringe, 7,500 iu in 0.75 ml syringe and 10,000 iu in 1 ml syringe to be delisted from 1 April 2020.				

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

29	DALTEPARIN (delisting)			
	Inj 12,500 iu in 0.5 ml syringe	99.96	10	Fragmin
	Inj 15,000 iu in 0.6 ml syringe	120.05	10	Fragmin
	Inj 18,000 iu in 0.72 ml syringe	158.47	10	Fragmin
	Note – Fragmin inj 12,500 iu in 0.5 ml syringe, 15,000 iu in 0.6 ml syringe and 18,000 iu in 0.72 ml syringe to be delisted from 1 January 2020.			
30	WARFARIN SODIUM († price)			
	Tab 1 mg	7.60	100	Marevan
	Tab 3 mg	11.80	100	Marevan
	Tab 5 mg	13.50	100	Marevan
31	ASPIRIN (↓ price and addition of HSS)			
	Tab 100 mg – 10% DV Nov-19 to 2022	10.80	990	Ethics Aspirin EC

CARDIOVASCULAR SYSTEM

38	PHENOXYBENZAMINE HYDROCHLORIDE (new listing)			
	Inj 50 mg per ml, 1 ml ampoule			
39	DIGOXIN († price and addition of HSS)			
	Tab 62.5 mcg – 1% DV Nov-19 to 2022	7.00	240	Lanoxin PG
	Tab 250 mcg – 1% DV Nov-19 to 2022	15.20	240	Lanoxin
41	LABELALOL (delisted)			
	Tab 400 mg			
	Note – labetalol tab 400 mg delisted 1 August 2019.			
43	FUROSEMIDE [FRUSEMIDE] (brand change)			
	Tab 40 mg – 1% DV Dec-19 to 2022	7.24	1,000	Apo-Furosemide
	Note – Diurin 40 tab 40 mg to be delisted from 1 December 2019.			
43	FUROSEMIDE [FRUSEMIDE] (new listing)			
	Oral liq 10 mg per ml – 1% DV Jan-20 to 2022	11.20	30 ml	Lasix
	Inj 10 mg per ml, 25 ml ampoule – 1% DV Jan-20 to 2022	60.65	6	Lasix
44	SPIRONOLACTONE († price and addition of HSS)			
	Oral liq 5 mg per ml – 1% DV Nov-19 to 2022	30.60	25 ml	Biomed
50	ILOPROST (brand change)			
	Inj 50 mcg in 0.5 ml ampoule – 1% DV Jan-20 to 2022	305.00	5	Clinect
	Note – Ilomedin inj 50 mcg in 0.5 ml ampoule to be delisted from 1 January 2020.			

DERMATOLOGICALS

54	CLOBETASOL PROPIONATE (↓ price and addition of HSS)			
	Crm 0.05% – 1% DV Nov-19 to 2022	2.18	30 g	Dermol
	Oint 0.05% – 1% DV Nov-19 to 2022	2.12	30 g	Dermol

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

55	CLOBETASOL PROPIONATE (↓ price and addition of HSS) Scalp app 0.05% – 1% DV Nov-19 to 2022	5.69	30 ml	Dermol
----	--	------	-------	---------------

GENITO-URINARY SYSTEM

58	INTRA-UTERINE DEVICE (↓ price and addition of HSS) IUD 29.1 mm length × 23.2 mm width – 1% DV Nov-19 to 2022	18.45	1	Choice TT380 Short
	IUD 33.6 mm length × 29.9 mm width – 1% DV Nov-19 to 2022	18.45	1	Choice TT380 Standard
	IUD 35.5 mm length × 19.6 mm width – 1% DV Nov-19 to 2022	15.50	1	Choice Load 375

INFECTIONS

73	CEFALEXIN (↓ price and addition of HSS) Cap 250 mg – 1% DV Nov-19 to 2022	3.33	20	Cephalexin ABM
73	CEFUROXIME (↑ price and addition of HSS) Tab 250 mg – 1% DV Feb-20 to 2022	45.93	50	Zinnat
73	CEFTRIAXONE (brand change) Inj 500 mg vial – 1% DV Jan-20 to 2022	0.89	1	Ceftriaxone-AFT
	Inj 1 g vial – 1% DV Jan-20 to 2022	3.99	5	Ceftriaxone-AFT
	Note – DEVA inj 500 mg and 1 g vial to be delisted from 1 January 2020.			
73	CEFTRIAXONE (↓ price and addition of HSS) Inj 2 g vial – 1% DV Jan-20 to 2022	1.98	1	Ceftriaxone-AFT
75	ROXITHROMYCIN (↑ price) → Tab dispersible 50 mg	8.29	10	Rulide D
80	ITRACONAZOLE (↑ price and addition of HSS) → Cap 100 mg – 1% DV Nov-19 to 2022	4.27	15	Itrazole
84	PENTAMIDINE ISETHIONATE (↑ price and addition of HSS) → Inj 300 mg vial – 1% DV Nov-19 to 2022	216.00	5	Pentacarinat

MUSCULOSKELETAL SYSTEM

94	PYRIDOSTIGMINE BROMIDE (↑ price and addition of HSS) Tab 60 mg – 1% DV Nov-19 to 2022	45.79	100	Mestinon
----	---	-------	-----	-----------------

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

NERVOUS SYSTEM

104	KETAMINE (new listing) Inj 100 mg per ml, 2 ml vial	155.60	5	Ketamine-Claris
105	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (↑ price and addition of HSS) Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022	225.00	10	Bupafen
	Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 1% DV Nov-19 to 2022	235.00	10	Bupafen
106	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↑ price and addition of HSS) Inj 2%, 5 ml ampoule – 1% DV Nov-19 to 2022	8.25	25	Lidocaine-Claris
106	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE (↑ price and addition of HSS) Inj 1% with adrenaline 1:100,000, 5 ml ampoule – 1% DV Nov-19 to 2022	29.00	10	Xylocaine
107	PARACETAMOL (↑ price and addition of HSS) Suppos 25 mg – 1% DV Nov-19 to 2022	58.50	20	Biomed
	Suppos 50 mg – 1% DV Nov-19 to 2022	58.50	20	Biomed
108	FENTANYL (↑ price and addition of HSS) Inj 10 mcg per ml, 100 ml bag – 1% DV Nov-19 to 2022	220.00	10	Biomed
112	ETHOSUXIMIDE (pack size change) Cap 250 mg	140.88	100	Zarontin
	Note – the 200 tab pack (Pharmacode 208876) to be delisted from 1 November 2019.			
117	AMISULPRIDE (↑ price and addition of HSS) Tab 100 mg – 1% DV Nov-19 to 2022	5.15	30	Sulprix
	Tab 200 mg – 1% DV Nov-19 to 2022	14.96	60	Sulprix
117	CHLORPROMAZINE HYDROCHLORIDE (new listing) Tab 10 mg – 1% DV Jan-20 to 2022	14.83	100	Largactil
	Tab 25 mg – 1% DV Jan-20 to 2022	15.62	100	Largactil
	Tab 100 mg – 1% DV Jan-20 to 2022	36.73	100	Largactil
	Inj 25 mg per ml, 2 ml ampoule – 1% DV Jan-20 to 2022	30.79	10	Largactil

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

130	FLUDARABINE PHOSPHATE (↑ price and addition of HSS) Inj 50 mg vial – 1% DV Nov-19 to 2022	576.45	5	Fludarabine Ebewe
142	CALCIUM FOLINATE (↑ price and addition of HSS) Inj 10 mg per ml, 10 ml vial – 1% DV Jan-20 to 2022	9.49	1	Calcium Folate Sandoz
	Inj 10 mg per ml, 35 ml vial – 1% DV Nov-19 to 2022	25.14	1	Calcium Folate Sandoz

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

142	CALCIUM FOLINATE (delisting) Inj 10 mg per ml, 10 ml vial	7.33	1	Calcium Folate Ebewe
	Note – Calcium Folate Ebewe inj 10 mg per ml, 10 ml vial to be delisted from 1 January 2020.			
142	MESNA (↑ price and addition of HSS)			
	Tab 400 mg – 1% DV Nov-19 to 2022	314.00	50	Uromitexan
	Tab 600 mg – 1% DV Nov-19 to 2022	448.50	50	Uromitexan
	Inj 100 mg per ml, 4 ml ampoule – 1% DV Nov-19 to 2022	177.45	15	Uromitexan
	Inj 100 mg per ml, 10 ml ampoule – 1% DV Nov-19 to 2022	407.40	15	Uromitexan
151	ADALIMUMAB (amended restriction criteria – new criteria shown only)			
	→ Inj 20 mg per 0.4 ml syringe	1,599.96	2	Humira
	→ Inj 40 mg per 0.8 ml pen	1,599.96	2	HumiraPen
	→ Inj 40 mg per 0.8 ml syringe	1,599.96	2	Humira
	Restricted			
	Initiation – severe Behcet’s disease			
	Any relevant practitioner			
	<i>Re-assessment required after 3 months</i>			
	All of the following:			
	1 The patient has severe Behcet’s disease that is significantly impacting the patient’s quality of life (see Notes); and			
	2 Either:			
	2.1 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has not responded adequately to treatment with infliximab (see Notes); or			
	2.2 The patient has severe ocular, neurological, gastrointestinal, rheumatological, mucocutaneous and/or vasculitic symptoms and has experienced intolerable side effects from treatment with infliximab; and			
	3 The patient is experiencing significant loss of quality of life; and			
	4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.			
	Notes: Behcet’s disease diagnosed according to the International Study Group for Behcet’s disease. Lancet 1990;335(8697):1078-80. Quality of life measured using an appropriate quality of life scale such as that published in Gilworth et al, J Rheumatol. 2004;31:931-7			
	Continuation – severe Behcet’s disease			
	Any relevant practitioner			
	<i>Re-assessment required after 6 months</i>			
	Both:			
	1 Patient has had a good clinical response to initial treatment with measurably improved quality of life; and			
	2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

159 BEVACIZUMAB (amended restriction criteria)

→ Inj 25 mg per ml, 4 ml vial

→ Inj 25 mg per ml, 16 ml vial

Restricted

Initiation – Recurrent Respiratory Papillomatosis

Otolaryngologist

Re-assessment required after 12 months

All of the following:

- 1 Maximum of 6 doses; and
- 2 The patient has recurrent respiratory papillomatosis; and
- 3 The treatment is for intra-lesional administration

Continuation – Recurrent Respiratory Papillomatosis

Otolaryngologist

Re-assessment required after 12 months

All of the following:

- 1 Maximum of 6 doses; and
- 2 The treatment is for intra-lesional administration; and
- 3 There has been a reduction in surgical treatments or disease regrowth as a result of treatment.

Initiation – ocular conditions

Either:

- 1 Ocular neovascularisation; or
- 2 Exudative ocular angiopathy.

169 RITUXIMAB (amended restriction criteria – new criteria shown only)

→ Inj 10 mg per ml, 10 ml vial..... 1,075.50 2 Mabthera

→ Inj 10 mg per ml, 50 ml vial..... 2,688.30 1 Mabthera

Restricted

Initiation – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Re-assessment required after 6 months

Both:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 Either:
 - 2.1 The patient has experienced a severe episode or attack of NMOSD (rapidly progressing symptoms and clinical investigations supportive of a severe attack of NMOSD); or
 - 2.2 All of the following:
 - 2.2.1 The patient has experienced a breakthrough attack of NMOSD; and
 - 2.2.2 The patient is receiving treatment with mycophenolate; and
 - 2.2.3 The patients is receiving treatment with corticosteroids.

Continuation – Neuromyelitis Optica Spectrum Disorder (NMOSD)

Relevant specialist or medical practitioner on the recommendation of a relevant specialist.

Re-assessment required after 2 years

All of the following:

- 1 One of the following dose regimens is to be used: 2 doses of 1,000 mg rituximab administered fortnightly, or 4 doses of 375 mg/m² administered weekly for four weeks; and
- 2 The patients has responded to the most recent course of rituximab; and
- 3 The patient has not received rituximab in the previous 6 months.

continued...

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

continued...

Initiation – Severe Refractory Myasthenia Gravis

Neurologist or medical practitioner on the recommendation of a neurologist.

Re-assessment required after 2 years

Both:

1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and

2 Either:

2.1 Treatment with corticosteroids and at least one other immunosuppressant for at least a period of 12 months has been ineffective; or

2.2 Both:

2.2.1 Treatment with at least one other immunosuppressant for a period of at least 12 months; and

2.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

Continuation – Severe Refractory Myasthenia Gravis

Neurologist or medical practitioner on the recommendation of a neurologist.

Re-assessment required after 2 years

All of the following:

1 One of the following dose regimens is to be used: 375 mg/m² of body surface area per week for a total of four weeks, or 500 mg once weekly for four weeks, or two 1,000 mg doses given two weeks apart; and

2 An initial response lasting at least 12 months was demonstrated; and

3 Either:

3.1 The patient has relapsed despite treatment with corticosteroids and at least one other immunosuppressant for a period of at least 12 months; or

3.2 Both

3.2.1 The patient's myasthenia gravis has relapsed despite treatment with at least one immunosuppressant for a period of at least 12 months; and

3.2.2 Corticosteroids have been trialed for at least 12 months and have been discontinued due to unacceptable side effects.

186	AZATHIOPRINE (brand change)		
	Tab 25 mg – 1% DV Jan-20 to 2022	7.35	60
	Tab 50 mg – 1% DV Jan-20 to 2022	7.60	100
	Note – Imuran tab 25 mg and 50 mg to be delisted from 1 January 2020.		

186	AZATHIOPRINE (↑ price and addition of HSS)		
	Inj 50 mg vial – 1% DV Nov-19 to 2022	199.00	1
			Imuran

RESPIRATORY SYSTEM AND ALLERGIES

189	CETIRIZINE HYDROCHLORIDE (↑ price and addition of HSS)		
	Tab 10 mg – 1% DV Nov-19 to 2022	1.12	100
			Zista

189	IPRATROPIUM BROMIDE (↑ price and addition of HSS)		
	Nebuliser soln 250 mcg per ml, 2 ml ampoule		
	– 1% DV Jan-20 to 2022	11.73	20
			Univent

193	MONTelukAST (brand change)		
	Tab 4 mg – 1% DV Jan-20 to 2022	4.25	28
	Tab 10 mg – 1% DV Jan-20 to 2022	3.95	28
	Note – Apo-Montelukast tab 4 mg and 10 mg to be delisted from 1 January 2020.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

194	CAFFEINE CITRATE (↑ price and addition of HSS) Oral liq 20 mg per ml (caffeine 10 mg per ml) – 1% DV Nov-19 to 2022	15.10	25 ml	Biomed
	Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – 1% DV Nov-19 to 2022	63.25	5	Biomed
194	THEOPHYLLINE (new listing) Tab long-acting 250 mg – 1% DV Jan-20 to 2022	23.02	100	Nuelin-SR
	Oral liq 80 mg per 15 ml – 1% DV Jan-20 to 2022	16.60	500 ml	Nuelin
194	SODIUM CHLORIDE (↑ price and addition of HSS) Nebuliser soln 7%, 90 ml bottle – 1% DV Nov-19 to 2022	24.50	90 ml	Biomed

SENSORY ORGANS

196	CHLORAMPHENICOL (addition of HSS) Eye drops 0.5% – 1% DV Nov-19 to 2022	1.54	10 ml	Chlorafast
198	SODIUM CROMOGLICATE (new listing) Eye drops 2% – 1% DV Jan-20 to 2022	1.79	5 ml	Rexacrom
200	TIMOLOL (delisting) Eye drops 0.25%, gel forming	3.30	2.5 ml	Timoptol XE
	Note – Timoptol XE eye drops 0.25%, gel forming to be delisted from 1 January 2020.			

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

211	COAL TAR (↑ price and addition of HSS) Soln BP – 1% DV Nov-19 to 2022	36.25	200 ml	Midwest
212	MAGNESIUM HYDROXIDE (new listing) Suspension			
212	SODIUM BICARBONATE (new listing) Powder BP – 1% DV Jan-20 to 2022	10.05	500 g	Midwest
213	SYRUP (pack size change) Liq (pharmaceutical grade) – 1% DV Jan-20 to 2022	14.95	500 ml	Midwest
	Note – Midwest liq (pharmaceutical grade), 2,000 ml bottle pack to be delisted from 1 January 2020.			

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 August 2019 (continued)

VACCINES

234 HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] (amended restriction criteria – new criteria shown only)

➔ Inj 270 mcg in 0.5 ml syringe – **0% DV Jun-17 to 2020** 0.00 10 **Gardasil 9**

Restricted

Initiation – (Recurrent Respiratory Papillomatosis)

All of the following:

1 Either:

1.1 Maximum of two doses for children aged 14 years and under; or

1.2 Maximum of three doses for people aged 15 years and over.

2 The patient has recurrent respiratory papillomatosis; and

3 The patient has not previously had an HPV vaccine.

Index

Pharmaceuticals and brands

A	
Adalimumab.....	11
Amisulpride.....	10
Apo-Furosemide.....	8
Aspegic.....	7
Aspirin.....	8
Azamun.....	13
Azathioprine.....	13
B	
Bevacizumab.....	12
Bupafen.....	10
Bupivacaine hydrochloride with fentanyl.....	10
C	
Caffeine citrate.....	14
Calcium folinate.....	10, 11
Calcium Folate Ebewe.....	11
Calcium Folate Sandoz.....	10
Cefalexin.....	9
Ceftriaxone.....	9
Ceftriaxone-AFT.....	9
Cefuroxime.....	9
Cephalexin ABM.....	9
Cetirizine hydrochloride.....	13
Chlorafast.....	14
Chloramphenicol.....	14
Chlorpromazine hydrochloride.....	10
Choice Load 375.....	9
Choice TT380 Short.....	9
Choice TT380 Standard.....	9
Clobetasol propionate.....	8, 9
Coal tar.....	14
D	
Dalteparin.....	7, 8
Dermol.....	8, 9
Digoxin.....	8
E	
Ethics Aspirin EC.....	8
Ethosuximide.....	10
F	
Fentanyl.....	10
Ferodan.....	7
Ferrous sulfate.....	7
Ferrous sulphate.....	7
Ferrum H.....	7
Fludarabine Ebewe.....	10
Fludarabine phosphate.....	10
Fragmin.....	7, 8
Frusamide.....	8
Furosemide [Frusamide].....	8
G	
Gardasil 9.....	15
H	
Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV].....	15
Humira.....	11
HumiraPen.....	11
Hyaluronic acid with lidocaine [Lignocaine].....	7
Hydrocortisone acetate with pramoxine hydrochloride.....	7
I	
Iloprost.....	8
Imuran.....	13
Intra-uterine device.....	9
Ipratropium bromide.....	13
Iron polymaltose.....	7
Itraconazole.....	9
Itrazole.....	9
K	
Ketamine.....	10
Ketamine-Clarix.....	10
L	
Labetalol.....	8
Lactulose.....	7
Laevolac.....	7
Lanoxin.....	8
Lanoxin PG.....	8
Largactil.....	10
Lasix.....	8
Lidocaine-Clarix.....	10
Lidocaine [Lignocaine] hydrochloride.....	10
Lidocaine [Lignocaine] hydrochloride with adrenaline.....	10
Lignocaine.....	7, 10
Lysine acetylsalicylate.....	7
M	
Mabthera.....	12
Magnesium hydroxide.....	14
Marevan.....	8
Mesna.....	11
Mestison.....	9
Micolette.....	7
Montelukast.....	13
Montelukast Mylan.....	13
N	
Nuelin.....	14
Nuelin-SR.....	14
P	
Paracetamol.....	10
Pentacarinat.....	9
Pentamidine isethionate.....	9
Phenoxybenzamine hydrochloride.....	8
Pyridostigmine bromide.....	9

Index

Pharmaceuticals and brands

Pyridoxine hydrochloride	7	T	
R		Theophylline	14
Ranitidine.....	7	Timolol	14
Rexacrom	14	Timoptol XE	14
Rituximab	12	U	
Roxithromycin.....	9	Univent	13
Rulide D.....	9	Uromitexan	11
S		W	
Sodium bicarbonate	14	Warfarin sodium.....	8
Sodium chloride.....	14	X	
Sodium citrate with sodium lauryl sulphoacetate...	7	Xylocaine	10
Sodium cromoglicate	14	Z	
Spirolactone.....	8	Zantac.....	7
Sulprix	10	Zarontin	10
Syrup.....	14	Zinnat	9
		Zista	13



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990

Fax: 64 4 460 4995

Website: www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3694 (Print)

ISSN 1179-3708 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand